Lin BioScience, Inc. (6696.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$159.00 (+1.60%) as of
Key statistics
- Market cap
- 131.84B
- EPS (TTM)
- -1.90
- Dividend yield
- 0.00%
- 52-week range
- 24.70 – 207.00
- Beta
- -0.25
- Profit margin
- 0.00%
- Volume
- 364.34k
About Lin BioScience, Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. Lin BioScience, Inc. is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.